1 / 10

Cholangiocarcinoma Market

Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules to the ampulla of Vater, and at the peribiliary glands. <br>

DelveInsight
Download Presentation

Cholangiocarcinoma Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHOLANGIOCARCINOMA(CCA) Market Insights, Epidemiology, and Market Forecast- 2028

  2. CHOLANGIOCARCINOMA (CCA) ORIGIN CLASSES BASIS Cholangiocarcinoma (CCA) is coded as intrahepatic bile duct carcinoma (C22.1), extrahepaticbile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of biliary tract (C24.8) or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9). It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA), but are now considered distinct entities based upon differences in their tumor biology and management. Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductulesto the ampulla of Vater, and at the peribiliaryglands. • DelveInsight © 2019 | All rights reserved

  3. CCA EPIDEMIOLOGY Diagnosed EU-5 Incidence Cholangiocarcinoma total diagnosed incident population in the 7MM was 18,470 in 2017. Among the EU5 countries, Germany had the highest CCA incident population with 4,471cases. US Incidence Prevalence Among all the countries, the higher Cholangiocarcinoma incidence was 6,768cases in the US in 2017. Males are more prone to Cholangiocarcinomaas compared to females among all countries. • DelveInsight © 2019 | All rights reserved

  4. Cholangiocarcinoma Market Outlook 01 02 03 04 05 Cholangiocarcinomamarket size in the 7MM* was found to USD 379.57 million in 2017 for the study period (2017-2028). CCA market size in Germany was found to be highest with USD 82.46 million in 2017, whereas Spain has the lowest share with USD 3.69 million in 2017. Cholangiocarcinoma market size for early stage includes surgery with chemotherapy and chemoradiation therapy. Among 7MM* the United States accounts for the highest CCA market size in comparison with EU-5 and Japan. The launch of various multiple-stage pipeline products will significantly revolutionize CCA market in future. *7MM includes:- United States; EU 5 (Germany, France, Spain, Italy, United Kingdom); Japan. www.website.com 4 • DelveInsight © 2019 | All rights reserved

  5. CCA Emerging Drugs and Companies Drug-Pemigatinib Company-Incyte Corporation Drug-Regorafenib Company- Bayer 03 01 Drug- Ivosidenib Company-Agios Pharmaceuticals Drug-Entrectinib Company-Roche 02 04 • DelveInsight © 2019 | All rights reserved

  6. Complete Information For complete information on Cholangiocarcinoma Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  7. About DelveInsight VISION ABOUT MISSION To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. • DelveInsight © 2019 | All rights reserved

  8. Service Offerings by DelveInsight 1 5 FORECASTING OPPORTUNITY ASSESSMENT 2 6 PIPELINE REPORT STORE 3 7 CONSULTING COMPETITIVE ANALYSIS 8 4 PHARMDELVE MARKET INTELLIGENCE • DelveInsight © 2019 | All rights reserved 9

  9. Contact Us info@delveinsight.com blog/delveInsight/ twitter/delveInsight +91-11-4568 9769 LinkedIn/delveInsight www.delveinsight.com • DelveInsight © 2019 | All rights reserved

  10. Thank You

More Related